Yamada Tomoya, Cohen Samuel M, Lake Brian G
Environmental Health Science Laboratory, Sumitomo Chemical Company, Ltd, Osaka, Japan.
Department of Pathology, Microbiology, and Immunology, and the Buffett Cancer Center, Sylvia Havlik Centennial Professor of Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Crit Rev Toxicol. 2025 Jun 27:1-38. doi: 10.1080/10408444.2025.2513332.
Constitutive androstane receptor (CAR) activators have long been known to enhance hepatocellular carcinogenesis in rodents, with the prototypic chemical being phenobarbital (PB). This has raised an ongoing controversy for the past 50 years as to whether this is relevant to human cancer risk. The established mode of action (MOA) for rodent liver tumor formation by CAR activators includes receptor activation, increased hepatocellular proliferation, altered liver foci and ultimately liver tumors. We previously published a critical review indicating the pivotal species difference that CAR activators are mitogenic agents in mouse and rat hepatocytes, but they do not stimulate hepatocellular proliferation in humans based on molecular downstream interaction differences, thus CAR activators pose no liver carcinogenic risk to humans (Yamada et al. ). Peroxisome proliferator-activated receptor alpha (PPARα) activators induce rodent liver tumors through a similar MOA, again involving increased hepatocellular proliferation, but are generally considered not relevant to human cancer risk. As with CAR activators, PPARα activators are mitogenic in rodent liver but not in other species, including humans. This species-specific effect of CAR and PPARα activators provides critical information useful for the overall risk assessments of these molecules, including pharmaceuticals, agrochemicals, food additives, and other chemicals. Overall, based on the available data for the specific molecular effects of these agents, the time has come to consider that chemicals for which the MOA of liver carcinogenicity observed in rodents has been clearly identified as either CAR- or PPARα-mediated (with other MOAs having been excluded) can be judged as having no relevance to human cancer risk without further investigations being necessary.
组成型雄烷受体(CAR)激活剂长期以来一直被认为会增强啮齿动物的肝细胞癌发生,典型的化学物质是苯巴比妥(PB)。在过去的50年里,这引发了一场持续的争议,即这是否与人类癌症风险相关。CAR激活剂导致啮齿动物肝肿瘤形成的既定作用模式(MOA)包括受体激活、肝细胞增殖增加、肝灶改变以及最终形成肝肿瘤。我们之前发表了一篇批判性综述,指出了关键的物种差异,即基于分子下游相互作用的差异,CAR激活剂在小鼠和大鼠肝细胞中是促有丝分裂剂,但它们不会刺激人类肝细胞增殖,因此CAR激活剂对人类不存在肝脏致癌风险(山田等人)。过氧化物酶体增殖物激活受体α(PPARα)激活剂通过类似的作用模式诱导啮齿动物肝肿瘤,同样涉及肝细胞增殖增加,但通常被认为与人类癌症风险无关。与CAR激活剂一样,PPARα激活剂在啮齿动物肝脏中具有促有丝分裂作用,但在包括人类在内的其他物种中则没有。CAR和PPARα激活剂的这种物种特异性效应为这些分子(包括药物、农用化学品、食品添加剂和其他化学品)的整体风险评估提供了关键信息。总体而言,根据这些药物特定分子效应的现有数据,现在是时候考虑对于那些在啮齿动物中观察到的肝脏致癌作用模式已被明确确定为CAR或PPARα介导(且已排除其他作用模式)的化学物质,可以判断它们与人类癌症风险无关,无需进一步调查。